Calcitriol in the management of renal osteodystrophy

Seminars in Dialysis

Volumn 9, Issue 4, 1996, Pages 316-325

  Coburn, Jack W ^a,b   Frazao, Joao ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001339737     PISSN: 08940959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-139x.1996.tb00687.x     Document Type: Article

References (77)

1. 3 in uremic man. N Engl J Med 287:891-895, 1972
2. 3 derivatives in the treatment of renal bone disease: Justification and optimal modalities of administration. Nephron 71: 254-283, 1995
3. 3 on mineral metabolism in man. I. Effects on net absorption of phosphorus. Am J Clin Nutr 30:1064-1070, 1977
4. Slatopolsky E, Weerts C, Thielan J, Horst RL, Harter H, Martin KJ: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 74:2136-2143, 1984
5. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ: Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 321:274-279, 1989
6. Dunlay R, Rodriguez M, Felsenfeld AJ, Llach F: Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) in dialysis. Kidney Int 36:1093-1098, 1989
7. Coburn JW, Didomenico NC, Bryce GF, Bassett LW, Shupien SA, Wong EGC, Miller RB, Bennett CM, Gold RH, Mallon JP, Miller ON, Chang PC: Prospective, double-blind trial with calcitriol in the prophylaxis of bone disease in asymptomatic dialysis patients, in Vitamin D: Chemical, Biochemical, and Clinical Endocrinology of Calcium Metabolism, edited by Norman AW, Schaeffer K, Grigoleit H-G, V. Herrath D, Berlin, deGruyter, 1982, p. 833
8. Baker LR, Muir JW, Sharman VL, Abrams SM, Greenwood RN, Cattell WR, Goodwin FJ, Marsh FP, Adami S, Hately W, Hattersly LA, Morgan AG, Papapoulos SE, Revell PA, Tucker AK, Chaput de Saintonge DM, O'Riordan JLH: Controlled trial of calcitriol in hemodialysis patients. Clin Nephrol 26:185-191, 1986
9. Memmos DE, Eastwood JB, Talner LB, Gower PE, Curtis JR, Phillips ME, Carter GD, Alaghband-Zadeh J, Roberts AP, De Wardener HE: Double-blind trial of oral 1,25-dihydroxy vitamin D3 versus placebo in asymptomatic hyperparathyroidism in patients receiving maintenance haemodialysis. Br Med J 282:1919-1924, 1981
10. Van der Merwe WM, Rodger RSC, Grant AC, Logue FC, Cowan RA, Beastall GH, Junor BJR, Briggs JD: Low calcium dialysate and high-dose oral calcitriol in the treatment of secondary hyperparathyroidism in haemodialysis patients. Nephrol Dial Transplant 5:874-877, 1990
11. Fukagawa M, Kitaoka M, Yi H, Fukuda N, Matsumoto T, Ogata E, Kurokawa K: Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. Nephron 68:221-228, 1994
12. Fukagawa M, Orazaki R, Takano K, Kaname S-Y, Ogata E, Kitoaka M, Karada S-I, Sekine N, Matsumoto T, Kurokawa K: Regression of parathyroid hyperplasia by calcitriol-pulse therapy in patients on long-term dialysis. N Engl J Med 323:421-422, 1990
13. 3 pulse therapy' in hemodialysis patients with severe secondary hyperparathyroidism. Nephron 57:23-28, 1991
14. 3. Nephron 58:288-294, 1991
15. Perez-Mijares R, Gomez-Fernandez P, Almaraz-Jimenez M, Ramos-Diaz M, Rivero-Bohorquez J: Treatment of severe secondary hyperparathyroidism with administration of calcium carbonate, intermittent high oral doses of 1,25-dihydroxy vitamin D3 and dialysate with 3 mEq/1 calcium concentration. Am J Nephrol 13:149-154, 1993
16. Martin KJ, Ballal HS, Domoto DT, Blalock S, Weindel M: Pulse oral calcitriol for the treatment of hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis: Preliminary observations. Am J Kidney Dis 19:540-545, 1992
17. Cannella G, Bonucci E, Rolla D, Ballanti P, Moriero E, De Grandi R, Augeri C, Claudiani F, Di Maio G: Evidence of healing of secondary hyperparathyroidism in chronically hemodialyzed uremic patients treated with long-term intravenous calcitriol. Kidney Int 46:1124-1132, 1994
18. Llach F, Hervas J, Cerezo S: The importance of dosing intravenous calcitriol in dialysis patients with severe hyperparathyroidism. Am J Kidney Dis 26:845-851, 1995
19. Malberti F, Surian M, Cosci P: Effect of chronic intravenous calcitriol on parathyroid function and set point of calcium in dialysis patients with refractory secondary hyperparathyroidism. Nephrol Dial Transplant 7:822-828, 1992
20. Herrmann P, Ritz E, Schmidt-Gayk H, Schäfer I, Geyer J, Nonnast-Daniel B, Koch K-M, Weber U, Hörl W, Haas-Wörle A, Kühn K, Bierther B, Schneider P: Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: A randomized prospective trial. Nephron 67:48-53, 1994
21. Bechtel U, Mücke C, Feucht HE, Schiffl H, Sitter T, Held E: Limitations of pulse oral calcitriol therapy in continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 25:291-296, 1995
22. Lind L, Wengle B, Wide L, Wrege U, Ljunghall S: Suppression of serum parathyroid hormone levels by intravenous alphacalcidol in uremic patients on maintenance hemodialysis: A pilot study. Nephron 48:296-299, 1988
23. 3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis. Nephron 53:194-200, 1989
24. Moriniere P, Cohen-Solal M, Belbrik S, Boudalliez, Marie A, Westeel P, Renaud H, Fievet P, Lalau J, Sebert JL, Fournier A: Disappearance of aluminic bone disease in a long term asymptomatic dialysis population restricting Al(OH)3 intake: Emergence of an idiopathic adynamic bone disease not related to aluminum. Nephron 53:93-101, 1989
25. Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, Saiphoo C, Fenton SS, Segre GV: The spectrum of bone disease in end-stage renal failure - An evolving disorder. Kidney Int 43:436-435, 1993
26. Hou SH, Zhao J, Ellman CF, Hu J, Griffin Z, Spiegel DM, Bourdeau JE: Calcium and phosphorus fluxes during hemodialysis with low calcium dialysate. Am J Kidney Dis 18:217-224, 1991
27. Hercz G, Pei Y, Greenwood C, Manuel A, Saiphoo C, Goodman WG, Segre GV, Fenton S, Sherrard DJ: Aplastic osteodystrophy without aluminum: The role of "suppressed" parathyroid function. Kidney Int 44:860-866, 1993
28. Brown RC, Aston JP, Weeks I, Woodhead S: Circulating intact parathyroid hormone measured by a two-site immunochemiluminometric assay. J Clin Endocrinol Metab 65:407-414, 1987
29. Nussbaum SR, Potts JT JR.: Immunoassays for parathyroid hormone 1-84 in the diagnosis of hyperparathyroidism. J Bone Miner Res 6 (Suppl. 2):S43-S50, 1991
30. Quarles LD, Lobaugh B, Murphy G: Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 75:145-150, 1992
31. Solal MC, Sebert JL, Boudailliez B, Annick M, Moriniere P, Gueris J, Bouillon R, Fournier A: Comparison of intact, midregion, and carboxyl terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients. J Clin Endocrinol Metab 73: 516-524, 1991
32. Hercz G, Pei Y, Sherrard DJ, Segre G, Chan W: The spectrum of fibrotic bone disease. J Am Soc Nephrol 4:697, 1993 (abstract)
33. 3 in experimental renal hyperparathyroidism. Kidney Int 44:1259-1265, 1993
34. Angelini D, Carlini A, Mazzotta L, Mei E, Grasse R, Neri M, Fiorini I, Antonelli A: Immunologic disturbances and levels of parathyroid hormone in uremic patients in replacement dialysis therapy. Clin Nephrol 42:246-250, 1994
35. Coburn JW, Sherrard DJ, Ott SM, Didomenico NC, Brickman AS, Singer FR: Use of active vitamin D sterols in end-stage renal failure, in Proceedings of the 4th International Congress on Calciotropic Hormones, edited by CANNIGIA A, Genova, Medical Systems, S.p.A., 1984, p. 27
36. Quarles LD, Davidai GA, Schwab SJ, Bartholomay DW, Lobaugh B: Oral calcitriol and calcium: Efficient therapy for uremic hyperparathyroidism. Kidney Int 34:840-844, 1988
37. Salusky IB, Goodman WG, Horst R, Segre GV, Kim L, Norris KC, Adams JS, Holloway M, Fine RN, Coburn JW: Pharmacokinetics of calcitriol in CAPD/CCPD patients. Am J Kidney Dis 16:126-132, 1990
38. Coburn JW: Use of oral and parenteral calcitriol in the treatment of renal osteodystrophy. Kidney Int 38(Suppl 29):S54-S61, 1990
39. Gallieni M, Brancaccio D, Padovese P, Rolla D, Bedani P, Colantonio G, Bronzieri C, Bagni B, Tarolo G, Italian Group for the Study of Intravenous Calcitriol: Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Kidney Int 42:1191-1198, 1992
40. Dressler R, Laut J, Lynn RI, Ginsberg N: Long-term high dose intravenous calcitriol therapy in end-stage renal disease patients with severe secondary hyperparathyroidism. Clin Nephrol 43:324-331, 1995
41. Fischer ER, Harris DCH: Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 40:216-220, 1993
42. Quarles LD, Yohay DA, Carroll BA, Spritzer CE, Minda SA, Bartholomay D, Lobaugh BA: Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 45:1710-1721, 1994
43. Levine BS, Song MM: Pharmacokinetics and efficacy of pulse oral versus intravenous calcitriol in hemodialysis patients. J Am Soc Nephrol 5:889, 1996 (in press)
44. Faugere M-C, Friedler RM, Malluche HH: Efficacy and limitations of pulse IV and pulse oral 1,25 vit. D therapy in treatment of hyperparathyroidism in patients on long term dialysis. J Am Soc Nephrol 4:695, 1993 (abstract)
45. Salusky IB, Ramirez JA, Belin T, Segre GV, Goodman WG: Pulse calcitriol therapy: A prospective randomized trial. J Am Soc Nephrol 5:855, 1994 (abstract)
46. Mohini R, Lester C, Szromba C, Rao DS, Narins RG: Problems with the use of intravenous calcitriol in the management of severe secondary hyperparathyroidism in patients on chronic hemodialysis. J Am Soc Nephrol 2:698, 1992 (abstract)
47. Rodriguez M, Felsenfeld AJ, Williams C, Pederson JA, Llach F: The effect of long-term calcitriol administration on parathyroid function in hemodialysis patients. J Am Soc Nephrol 2:1014-1020, 1991
48. Malberti F, Scanziani R, Corradi B, Dozio B, Bonforte G, Imbasciati E, Surian M: High-dose oral calcitriol and zero calcium peritoneal solutions in CAPD patients with refractory secondary hyperparathyroidism. Nephrol Dial Transplant 9:1813-1815, 1994
49. Sprague SM, Moe SM: Safely and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol. Am J Kidney Dis 19:532-539, 1992
50. Coburn JW, Salusky IB: Control of serum phosphorus in uremia. N Engl J Med 320:1140-1142, 1989
51. Goodman WG, Ramirez JA, Belin TR, Chon Y, Gales B, Segre GV, Salusky IB: Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 46:1160-1166, 1994
52. Gonella M, Calabrese G, Aleo AG, Vagelli G, Deambrogio P: Calcitriol pulse therapy for severe hyperparathyroidism or calcium salts as phosphate binders in renal dialysis patients. Nephron 71:350-353, 1995
53. Slatopolsky E, Weerts C, Norwood K, Giles K, Fryer P, Finch J, Windus D, Delmez J: Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism. Kidney Int 36: 897-903, 1989
54. Fukagawa M, Fukuda N, Yi H, Kurokawa K: Resistance of parathyroid cell to calcitriol as a cause of parathyroid hyperfunction in chronic renal failure [editorial]. Nephrol Dial Transplant 10:315-319, 1995
55. 3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 92:1436-1443, 1993
56. Arnold A, Brown MF, Ureña P, Gaz RD, Sarfati E, Drücke TB: Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest 95:2047-2053, 1995
57. 3 and 22-oxacalcitriol on phosphate and calcium metabolism. Kidney Int 43:561-566, 1993
58. Kubrusly M, Gagné E-R, Ureña P, Hanrotel C, Chabinis S, Lacour B, Drücke TB: Effect of 22-oxa-calcitriol on calcium metabolism in rats with severe secondary hyperparathyroidism. Kidney Int 44:551-556, 1993
59. Morii H, Ogura Y, Suzuki S, Kurokawa K, Kawaguchi Y, Nishizawa Y, Inoue S, Suzuki Y, Maeda K, Fujimi S, Koshikawa S, Mimura N, Shimizu N, Kimura S: PTH suppressing effect of flocalcitriol in haemodialysed patients. Nephrol Dial Transplant 8:1001, 1993 (abstract)
60. 2, suppresses PTH secretion in uremic rats in the absence of hypercalcemia. J Bone Mineral Res 10(Supp. 1):S116, 1995 (abstract)
61. 2: A new look at an "old" compound. Nephrol Dial Transplant 1996 (in press)
62. Fox J, Hadfield S, Petty BA, Conklin RL, Nerneth EP: NPS-R-568 inhibits parathyroid hormone secretion and stimulates calcitonin secretion in hyperparathyroid rats with chronic renal failure. J Am Soc Nephrol 4:719, 1993
63. Nordal KP, Dahl E: Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. J Clin Endocrinol Metab 67: 929-936, 1988
64. 3 in the treatment of renal osteodystrophy in patients with moderate renal failure, in Clinical Disorders of Bone and Mineral Metabolism, edited by Frame B, Potts JT, JR., Amsterdam, Exerpta Medical, 1983, p.260
65. 3 administration in moderate renal failure: A prospective double-blind trial. Kidney Int 35:661-669, 1989
66. Hamdy NAT, Kanis JA, Beneton MNC, Brown CB, Juttmann JR, Jordans JGM, Josse S, Meyrier A, Lins RL, Fairey IT: Effect of alfacalcidol on natural course of bone disease in mild to moderate renal failure. Br Med J 310:358-363, 1995
67. Bianchi ML, Colantonio G, Campanini F, Rossi R, Valenti G, Ortolani S, Buccianti G: Calcitriol and calcium carbonate therapy in early chronic renal failure. Nephrol Dial Transplant 9:1595-1599, 1994
68. Nordal KP, Dahl E, Halse J, Ajitamadal A, Flatmark A: Long-term low-dose calcitriol in predialysis chronic renal failure: Can it prevent hyperparathyroid bone disease? Nephrol Dial Transplant 1995 (in press)
69. Cundy T, Hand DJ, Oliver DO, Woods CG, Wright FW, Kanis JA: Who gets renal bone disease before beginning dialysis? Br Med J 290:271-275, 1985
70. Pazianas M, Phillips ME, Macrae KD, Eastwood JB: Identification of risk factors for radiographic hyperparathyroidism in 422 patients with end-stage renal disease: development of a clinical predictive index. Nephrol Dial Transplant 7:1098-1105, 1992
71. 3 in early renal failure. Annu Rev Med 43:227-237, 1992
72. 2D: Humoral and histomorphometric results. Miner Electrolyte Metab 12:375-382, 1986
73. 3 administration in a long-term follow-up. Kidney Int 28:783-790, 1985
74. Coen G, Mazzaferro S, Manni M, Fondi G, Perruzza I, Pasquali M, Taggi F: No acceleration and possibly slower progression of renal failure during calcitriol treatment in predialysis chronic renal failure. Nephrol Dial Transplant 9:1520, 1994
75. Bertoli M, Luisetto G, Ruffatti A, Urso M, Romagnoli G: Renal function during calcitriol therapy in chronic renal failure. Clin Nephrol 33:98-102, 1990
76. Christiansen C, Rodbro P, Christensen MS, Hartnack B: Is 1,25-dihydroxy-cholecalciferol harmful to renal function in patients with chronic renal failure? Clin Endocrinol 15:229-236, 1981
77. Naik RB, Cundy T, Robinson RHB, Russell RGG, Kanis JA: Effects of vitamin D metabolites and analogues on renal function. Nephron 28:17-25, 1981